BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Receptor Tyrosine Kinase 100%
• Cancer Cell 100%
• Upregulation 40%
• Kinase 20%
• Phosphotransferase 20%
• Product Inhibition 20%
• Small Hairpin RNA 20%
• Lapatinib 20%
• Dabrafenib 20%
• Afatinib 20%
• Canertinib 20%
• Vemurafenib 20%
• GRB2 20%
• Allele 20%
• Sensitization 20%
• MEK Inhibitor 20%
• Panitumumab 20%

Immunology and Microbiology

• Tyrosine 100%
• Colorectal Cancer Cell Line 100%
• Epidermal Growth Factor 60%
• Upregulation 40%
• Cancer Cell 20%
• Allele 20%
• Sensitization 20%
• Cetuximab 20%
• Epidermal Growth Factor Receptor Antibody 20%
• Gamma Urogastrone 20%
• Panitumumab 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase 100%
• Colorectal Carcinoma 100%
• Vemurafenib 33%
• Oncoprotein 33%
• Mitogen Activated Protein Kinase Kinase Inhibitor 16%
• Lapatinib 16%
• Short Hairpin RNA 16%
• Encorafenib 16%
• Canertinib 16%
• Phosphotransferase Inhibitor 16%
• Dabrafenib 16%
• Afatinib 16%
• Panitumumab 16%
• Gamma Urogastrone 16%